Table 3. Univariate and multivariate analysis for cancer-specific survival and disease-free urvivlal.
|
Cancer-specific survival |
Disease-free survival |
|||||
|---|---|---|---|---|---|---|
| |
Univariate |
Multivariate |
Univariate |
Multivariate |
||
| Variable | P-value | HR (95% CI) | P-value | P-value | HR (95% CI) | P-value |
|
Age (years) | ||||||
| ⩽54 | ||||||
| >54 |
0.063 |
— |
— |
0.218 |
— |
— |
|
FIGO stage | ||||||
| I | 1.000 | < 0.001 | 1.000 | < 0.001 | ||
| II | 2.518 (0.819–7.743) | 0.107 | 2.659 (0.865–8.175) | 0.088 | ||
| III–IV |
< 0.001 |
6.783 (2.496–18.434) |
< 0.001 |
< 0.001 |
7.213 (2.652–19.618) |
< 0.001 |
|
Histologic grade | ||||||
| G1/G2 | 1.000 | 1.000 | ||||
| G3 |
0.040 |
1.362 (0.980–1.892) |
0.066 |
0.040 |
1.446 (1.043–2.005) |
0.027 |
|
Histological type | ||||||
| Serous | ||||||
| Mucinous | ||||||
| Endometrioid | ||||||
| Clear cell |
0.082 |
— |
— |
0.052 |
— |
— |
|
Residual tumour size | ||||||
| ⩽1 cm | 1.000 | 1.000 | ||||
| >1 cm |
< 0.001 |
1.995 (1.340–2.972) |
0.001 |
< 0.001 |
1.777 (1.197–2.637) |
0.004 |
|
Ascites | ||||||
| ⩽100 ml | ||||||
| >100 ml |
0.464 |
— |
— |
0.799 |
— |
— |
|
Serum CA-125 level | ||||||
| ⩽35 U ml−1 | ||||||
| >35 U ml−1 |
0.216 |
— |
— |
0.189 |
— |
— |
|
TNFAIP8 expression | ||||||
| Low | 1.000 | 1.000 | ||||
| High | < 0.001 | 1.852 (1.322–2.594) | < 0.001 | < 0.001 | 1.724 (1.235–2.407) | 0.001 |
Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; HR=hazard ratio; CI=confidence interval; TNFAIP8=tumour necrosis factor-α-induced protein 8.